Novel long-acting bronchodilators for COPD and asthma

British Journal of Pharmacology

Volumn 155, Issue 3, 2008, Pages 291-299

  Cazzola, M ^a   Matera, M G ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Aclidinium; Asthma; Bronchodilators; Carmoterol; Chronic obstructive pulmonary disease; Combination therapy; Indacaterol; Long acting antimuscarinic agents; NVA237; Ultra long acting agonists

Indexed keywords

4 ACETAMIDOPIPERIDINE DERIVATIVE; ACLIDINIUM; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CARMOTEROL; CHF 5407; FLUORINATED HYDROCARBON; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; GSK 159797; GSK 159802; GSK 233705; GSK 597901; GSK 656398; GSK 678007; GW 642444; INDACATEROL; IPRATROPIUM BROMIDE; LAS 35201; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ANTICHOLINERGIC EFFECT; ASTHMA; BRONCHODILATING ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG DURATION OF ACTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DUG ONSET OF ACTION; GLUCOSE BLOOD LEVEL; HEADACHE; HEART RATE; HUMAN; INOTROPISM; METERED DOSE INHALER; NONHUMAN; PATIENT COMPLIANCE; PHARMACOKINETICS; PLASMA CLEARANCE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; QT INTERVAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TACHYPHYLAXIS; VOLUNTEER;

ADRENERGIC BETA-AGONISTS; ANIMALS; ASTHMA; BRONCHODILATOR AGENTS; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; HUMANS; MUSCARINIC ANTAGONISTS; PATIENT COMPLIANCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 52949146750     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.284     Document Type: Review

References (68)

1. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R et al. (2007). Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 146: 545-555.
2. Acerbi D, Brambilla G, Kottakis I (2007). Advances in asthma and COPD management: delivering CFC-free inhaled therapy using Modulite technology. Pulm Pharmacol Ther 20: 290-303.
3. Anonymous (2007). Theravance, Inc. (THRX) Announces Positive Results of Clinical Program in Beyond Advair Collaboration. Available at: http://www.biospace.com/news_story.aspx?NewsEntityId=51071 Accessed 27 December 2007.
4. Arievich H, Potena A, Fonay K, Vogelmeier CF, Overend T, Smith J et al. (2006). Formoterol given either alone or together with tiotropium, reduces the rate of exacerbations in stable COPD patients. Eur Respir J 28: 430s.
5. Aubier M, Duval X, Knight H, Perry S, Majumdar T, Kaiser G et al. (2005). Indacaterol, a novel once-daily β2-agonist, is effective and well tolerated on multiple dosing in patients with mild-to-moderate COPD. Eur Respir J 26: 287s.
6. Barnes PJ (2004). The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med 117 (Suppl 12A): 24S-32S.
7. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M et al. (2008). Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 31: 143-178.
8. 2 adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 317: 762-770.
9. 2-agonist, provides sustained 24-h bronchodilation in asthma. Eur Respir J 29: 871-878.
10. 2-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. Pulm Pharmacol Ther 20: 740-749.
11. Bender BG (2002). Overcoming barriers to nonadherence in asthma treatment. J Allergy Clin Immunol 6 (Suppl): S554-S559.
12. Brookman LJ, Knowles LJ, Barbier M, Elharrar B, Fuhr R, Pascoe S (2007). Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma. Curr Med Res Opin 23: 3113-3122.
13. 2-adrenoreceptor agonists. Bioorg Med Chem Lett 17: 4012-4015.
14. Campbell LM (1999). Once-daily inhaled corticosteroids in mild to moderate asthma: improving acceptance of treatment. Drugs 58 (Suppl 4): 25-33.
15. Cazzola M, Andò F, Santus P, Ruggeri P, Di Marco F, Sanduzzi A et al. (2007). A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm Pharmacol Ther 20: 556-561.
16. Cazzola M, Centanni S, Santus P, Verga M, Mondoni M, di Marco F et al. (2004a). The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med 98: 1214-1221.
17. Cazzola M, Di Marco F, Santus P, Boveri B, Verga M, Matera MG et al. (2004b). The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 17: 35-39.
18. Cazzola M, Matera MG (2004). Long-acting bronchodilators are the first-choice option for the treatment of stable COPD. Chest 125: 9-11.
19. Cazzola M, Matera MG (2006). The effective treatment of COPD: anticholinergics and what else? Drug Discov Today: Ther Strateg 3: 277-286.
20. Cazzola M, Matera MG (2007). The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: a pilot study. Respir Med 101: 957-962.
21. 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 14: 775-783.
22. Celli BR, MacNee W (2004). ATS/ERS task force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23: 932-946.
23. Chiesi Farmaceutici (2004). Investigator's brochure: CHF 4226 (data on file).
24. Chuchalin AG, Tsoi AN, Richter K, Krug N, Dahl R, Luursema PB et al. (2007). Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study. Respir Med 101: 2065-2075.
25. Claxton AJ, Cramer J, Pierce CA (2001). A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23: 1296-1310.
26. Cooper N, Walker I, Knowles I (2006). NVA237 and tiotropium bromide demonstrate similar efficacy in an anesthetized rabbit model of methacholine-induced bronchoconstriction. NVA237 demonstrates a reduced systemic pharmacological effect on cardiovascular parameters. Proc Am Thor Soc 3: A117.
27. Fitzgerald MF, Fox JC (2007). Emerging trends in the therapy of COPD: bronchodilators as mono- and combination therapies. Drug Discov Today 12: 472-478.
28. Gavalda A, Miralpeix M, Ramos I, Vilella D, Sentellas S, Alberti J et al. (2007). Aclidinium bromide, a novel muscarinic receptor antagonist combining long residence at M3 receptors and rapid plasma clearance. Eur Respir J 30: 209s.
29. Gunawardena KA, Wild RN, Kirkpatrick J, Snape SD (2006). NVA237, a once-daily antimuscarinic, demonstrates sustained bronchodilation and is well tolerated in patients with reversible obstructive airways disease. Proc Am Thor Soc 3: A117.
30. Haeussermann S, Acerbi A, Brand P, Poli G, Meyer T (2006). Lung deposition of carmoterol in healthy subjects, patients with asthma and patients with COPD. Eur Respir J 28: 211s.
31. Joos G, Schelfhout V, Kanniess F, Ludwig-Sengpiel A, Garcia Gil E, Massana Montejo E (2007). Bronchodilator effects of aclidinium bromide, a novel long-acting anticholinergic, in COPD patients: a phase II study. Eur Respir J 30: 210s.
32. 2-agonists. Biol Pharm Bull 17: 1047-1052.
33. 2-selectivity of TA-2005, a newly developed bronchodilating agent, in isolated guinea-pig tissues. Jpn J Pharmacol 57: 175-185.
34. 2-agonist carmoterol following 7 days once daily dosing: comparison with twice daily formoterol in patient with persistent asthma. Eur Respir J 28: 665s.
35. Kuna P, Vinkler I, Overend T, Snape S, Tansley R (2007). Efficacy and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. Eur Respir J 30: 354s.
36. LaForce C, Alexander M, Deckelmann R, Fabbri LM, Aisanov Z, Cameron R et al. (2008). Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study. Allergy 63: 103-111.
37. Lipworth BJ, Grove A (1997). Evaluation of partial β-adrenoceptor agonist activity. Br J Clin Pharmacol 43: 9-14.
38. Lu S, Parekh DD, Kuznetsova O, Green SA, Tozzi CA, Reiss TF (2006). An oral selective M3 anticholinergic receptor antagonist in COPD. Eur Respir J 28: 772-780.
39. Magnussen H, Bugnas B, van Noord J, Schmidt P, Gerken F, Kesten S (2008). Improvements with tiotropium in COPD patients with concomitant asthma. Respir Med 102: 50-56.
40. Martinez FD (2005). Safety of long-acting β-agonists - an urgent need to clear the air. N Engl J Med 353: 2637-2639.
41. 2- adrenoceptor agonists. An emerging therapeutic option for asthma and COPD? Drugs 67: 503-515.
42. Miralpeix M, Gavalda A, Morcillo E, Cortijo J, Puig J, Ryder H et al. (2007). Assessment of the potency and duration of action of aclidinium bromide in guinea pig isolated trachea in vitro. Eur Respir J 30: 359s.
43. 2-adrenoceptor agonist, on human isolated bronchi. Eur Respir J 29: 575-581.
44. 2-agonist carmoterol given as a 2 mg qd dose; 8 days comparison with formoterol and placebo in patients with persistent asthma. \Eur Respir J 28: 665s.
45. National Asthma Education Prevention Program (2007). Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol 120 (5 Suppl): S94-S138.
46. Patacchini R, Bergamaschi M, Harrison S, Perillo P, Gigli PM, Janni A et al. (2007). In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonist. Eur Respir J 30: 25s.
47. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P et al. (2007). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176: 532-555.
48. Rabe K, Timmer W, Sagriotis A, Viel K (2008). Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD. Chest; doi 10.1378/chest.07-2138.
49. Rennard S, Bantje T, Centanni S, Chanez P, Chuchalin A, D'Urzo A et al. (2008). A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 102: 1033-1044; doi:10.1016/j.rmed.2008.02.001.
50. Rodrigo GJ, Nannini LJ (2007). Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis. Pulm Pharmacol Ther 20: 495-502.
51. 2-agonist carmoterol and tiotropium bromide in the control of airway changes induced by different challenges in guinea-pigs. Pulm Pharmacol Ther 20: 250-257.
52. Rossoni G, Manfredi B, Mazzetti R, Civelli M, Bongrani S, Berti F (2005). Positive interaction of the 2-agonist CHF 4226.01 with budesonide in the control of bronchoconstriction induced by acetaldehyde in the guinea-pigs. Br J Pharmacol 144: 422-429.
53. Schelfhout V, Joos G, Garcia Gil E, Massana Montejo E (2007). Bronchodilator/bronchoprotective effects of aclidinium bromide, a novel long-acting anticholinergic: a phase I study. Eur Respir J 30: 356s.
54. Sin DD, Man SF (2006). Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases. Eur J Pharmacol 533: 28-35.
55. Singh D, Brooks J, Hagan G, Cahn T, O'Connor B (2008). Triple therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax; doi:10.1136/thx.2007. 087213.
56. Singh D, Corris PA, Snape SD (2006). NVA237, a once-daily inhaled antimuscarinic, provides 24-h bronchodilator efficacy with comparable bronchodilation to albuterol in patients with moderate-tosevere COPD. Proc Am Thor Soc 3: A113.
57. 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther 324: 270-275.
58. Tamura G, Ohta K (2007). Adherence to treatment by patients with asthma or COPD: comparison between inhaled drugs and transdermal patch. Respir Med 101: 1895-1902.
59. Tashkin DP, Littner M, Andrews CP, Tomlinson L, Rinehart M, Denis-Mize K (2008). Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med 102: 479-487.
60. Thomas R, Eltringham E, Tansley R, Snape S (2006). Low systemic exposure of NVA237, an inhaled once-daily antimuscarinic bronchodilator, in healthy human volunteers. Proc Am Thor Soc 3: A725.
61. van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B et al. (2005). Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 26: 214-222.
62. van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A et al. (2006). Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 129: 509-517.
63. Villetti G, Bassani F, Bergamaschi M, Bolzoni PT, Amari G, Del Canale M et al. (2007). In vivo potent and long-lasting bronchodilator activity of muscarinic M3 receptor antagonist CHF5407. Eur Respir J 30: 26s.
64. Vogelmeier CF, Harari SA, Fonay K, Beier J, Overend T, Till D et al. (2006). Formoterol and tiotropium both improve lung function in stable COPD patients, with some additional benefit when given together. Eur Respir J 28: 429s.
65. 2-adrenoceptor agonist, TA-2005. Eur J Pharmacol 227: 403-409.
66. Yang WH, Martinot JB, Pohunek P, Beier J, Magula D, Cameron R et al. (2007). Tolerability of indacaterol, a novel once-daily beta2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study. Ann Allergy Asthma Immunol 99: 555-561.
67. 2-agonists in asthma: an overview of Cochrane systematic reviews. Respir Med 99: 384-395.
68. Wise RA, Tashkin DP (2007). Optimizing treatment of chronic obstructive pulmonary disease: an assessment of current therapies. Am J Med 120 (8 Suppl 1): S4-S13.